BioLife Solutions Incorporated and Corning Incorporated Announce Increased Cell Performance Through Product Combination
31 Outubro 2006 - 10:30AM
Business Wire
BioLife Solutions Inc. (OTC Bulletin Board: BLFS), a leading
manufacturer of proprietary cryopreservation solutions for cells
and tissue preservation, and Corning Incorporated (NYSE: GLW) today
announced the publication of a report that describes the benefits
of the combination of the BioLife CryoStor� CS5 with Corning�s
CellBIND� Surface. The integration of these complementary
technologies resulted in a significant increase in the survival and
attachment of LNCaP cells as compared to traditional solutions and
tissue culture treated (TCT) surfaces. The CryoStor/Corning
CellBIND Surface combined approach offers a distinct advantage to
the pharmaceutical, drug discovery, and toxicity testing industries
by enabling researchers to reduce time and effort presently
required to collect, store, retrieve and utilize high-quality
cryopreserved cells. This thereby increases productivity and
cost-effectiveness of in vitro screening processes. �This
validation of serum-free and protein-free CryoStor provides an
important endorsement of our preservation technology platform and
intellectual property portfolio,� said Mike Rice, chief executive
officer, BioLife Solutions. �The study jointly performed by Corning
and BioLife scientists demonstrates fundamental advantages that the
combined products offer to a broad industry base, including drug
discovery and cellular therapy.� Data from independent experiments
showed that the Cryostor solution and Corning CellBIND surface
product combination offered a 58-percent increase in
post-preservation cell survival when compared to traditional tissue
culture surface and serum and protein based freezing media. �It�s
important to note that cell survival was measured 24 hours
post-thaw, a much more relevant performance metric than immediate
post-thaw survival measurement, which often gives researchers a
false sense of practical cell function and viability,� added John
G. Baust, PhD, chief scientific officer, BioLife Solutions. �These
independently verified results confirm the benefits of using the
Corning CellBIND surface combined with the protein-free BioLife
CryoStorCS5 freezing solution to improve the survival of LNCaP
cells,� said Mark Beck, vice president and general manager, Corning
Life Sciences. �Our relationship with BioLife further demonstrates
our commitment to developing innovative technologies and/or
partnering with industry leaders to provide our global customers
with the solutions and expertise they require to improve
performance and results.� The report, titled �Enhanced Survival of
LNCaP Cells Following Cryopreservation Using the CryoStor CS5
Preservation Solutions and Corning CellBIND Surface,� was
co-authored by Corning Life Sciences and BioLife Solutions
scientists and will appear in an upcoming issue of Genetic
Engineering News. Additionally, a Corning application note
(SnAPPShot) on the performance results can be accessed by visiting
the following link on the Corning website:
http://www.corning.com/lifesciences/technical_information/techdocs
/snappshots_084_lncap_cryostor_cellbind.pdf. (Due to its length,
this URL may need to be copied/pasted into your Internet browser's
address field. Remove the extra space if one exists.) The�CryoStor
family of preservation solutions represents the next generation of
cryopreservation (freeze) media. Designed to prepare and preserve
cells in ultra-low temperature environments (-80oC to -196oC),
CryoStor provides a safe, protective environment for cells and
tissues during the freezing, storage, and thawing process. Through
modulating the cellular biochemical response to the
cryopreservation process, CryoStor provides for enhanced cell
viability and functionality while eliminating the need to include
serum, proteins or high levels of cytotoxic agents. The Corning
CellBIND surface is the first novel cell culture surface treatment
in more than 20 years. The surface enhances attachment, making it
easier to grow fastidious cells under difficult conditions
including reduced-serum and serum-free medium, and resulting in
higher cell yields. Developed by Corning scientists, this patented
(US Patent # 6,617,152) technology uses a microwave process for
treating the culture surface. This new process improves cell
attachment by incorporating significantly more oxygen into the cell
culture surface, rendering it more hydrophilic and increasing
surface stability. About Corning Corning Incorporated
(www.corning.com) is a diversified technology company that
concentrates its efforts on high-impact growth opportunities.
Corning combines its expertise in specialty glass, ceramic
materials, polymers and the manipulation of the properties of
light, with strong process and manufacturing capabilities to
develop, engineer and commercialize significant innovative products
for the telecommunications, information display, environmental,
semiconductor, and life sciences industries. About BioLife
Solutions BioLife Solutions develops, manufactures and markets
patented hypothermic storage and cryopreservation solutions for
cells, tissues, and organs. The Company�s proprietary
HypoThermosol� and CryoStor line of solutions are marketed directly
to companies, labs and academic institutions engaged in research
and commercial applications. BioLife�s line of serum free and
protein free preservation solutions are fully defined and
formulated to reduce or prevent preservation-induced, delayed-onset
cell damage and death. BioLife�s platform enabling technology
provides academic and clinical researchers significant improvement
in post-thaw cell, tissue, and organ viability and function. For
more information please visit BioLife Solutions website at
www.biolifesolutions.com. BioLife Solutions Inc. (OTC Bulletin
Board: BLFS), a leading manufacturer of proprietary
cryopreservation solutions for cells and tissue preservation, and
Corning Incorporated (NYSE: GLW) today announced the publication of
a report that describes the benefits of the combination of the
BioLife CryoStor(TM) CS5 with Corning's CellBIND(R) Surface. The
integration of these complementary technologies resulted in a
significant increase in the survival and attachment of LNCaP cells
as compared to traditional solutions and tissue culture treated
(TCT) surfaces. The CryoStor/Corning CellBIND Surface combined
approach offers a distinct advantage to the pharmaceutical, drug
discovery, and toxicity testing industries by enabling researchers
to reduce time and effort presently required to collect, store,
retrieve and utilize high-quality cryopreserved cells. This thereby
increases productivity and cost-effectiveness of in vitro screening
processes. "This validation of serum-free and protein-free CryoStor
provides an important endorsement of our preservation technology
platform and intellectual property portfolio," said Mike Rice,
chief executive officer, BioLife Solutions. "The study jointly
performed by Corning and BioLife scientists demonstrates
fundamental advantages that the combined products offer to a broad
industry base, including drug discovery and cellular therapy." Data
from independent experiments showed that the Cryostor solution and
Corning CellBIND surface product combination offered a 58-percent
increase in post-preservation cell survival when compared to
traditional tissue culture surface and serum and protein based
freezing media. "It's important to note that cell survival was
measured 24 hours post-thaw, a much more relevant performance
metric than immediate post-thaw survival measurement, which often
gives researchers a false sense of practical cell function and
viability," added John G. Baust, PhD, chief scientific officer,
BioLife Solutions. "These independently verified results confirm
the benefits of using the Corning CellBIND surface combined with
the protein-free BioLife CryoStorCS5 freezing solution to improve
the survival of LNCaP cells," said Mark Beck, vice president and
general manager, Corning Life Sciences. "Our relationship with
BioLife further demonstrates our commitment to developing
innovative technologies and/or partnering with industry leaders to
provide our global customers with the solutions and expertise they
require to improve performance and results." The report, titled
"Enhanced Survival of LNCaP Cells Following Cryopreservation Using
the CryoStor CS5 Preservation Solutions and Corning CellBIND
Surface," was co-authored by Corning Life Sciences and BioLife
Solutions scientists and will appear in an upcoming issue of
Genetic Engineering News. Additionally, a Corning application note
(SnAPPShot) on the performance results can be accessed by visiting
the following link on the Corning website:
http://www.corning.com/lifesciences/technical_information/techdocs
/snappshots_084_lncap_cryostor_cellbind.pdf. (Due to its length,
this URL may need to be copied/pasted into your Internet browser's
address field. Remove the extra space if one exists.) The CryoStor
family of preservation solutions represents the next generation of
cryopreservation (freeze) media. Designed to prepare and preserve
cells in ultra-low temperature environments (-80(degrees)C to
-196(degrees)C), CryoStor provides a safe, protective environment
for cells and tissues during the freezing, storage, and thawing
process. Through modulating the cellular biochemical response to
the cryopreservation process, CryoStor provides for enhanced cell
viability and functionality while eliminating the need to include
serum, proteins or high levels of cytotoxic agents. The Corning
CellBIND surface is the first novel cell culture surface treatment
in more than 20 years. The surface enhances attachment, making it
easier to grow fastidious cells under difficult conditions
including reduced-serum and serum-free medium, and resulting in
higher cell yields. Developed by Corning scientists, this patented
(US Patent # 6,617,152) technology uses a microwave process for
treating the culture surface. This new process improves cell
attachment by incorporating significantly more oxygen into the cell
culture surface, rendering it more hydrophilic and increasing
surface stability. About Corning Corning Incorporated
(www.corning.com) is a diversified technology company that
concentrates its efforts on high-impact growth opportunities.
Corning combines its expertise in specialty glass, ceramic
materials, polymers and the manipulation of the properties of
light, with strong process and manufacturing capabilities to
develop, engineer and commercialize significant innovative products
for the telecommunications, information display, environmental,
semiconductor, and life sciences industries. About BioLife
Solutions BioLife Solutions develops, manufactures and markets
patented hypothermic storage and cryopreservation solutions for
cells, tissues, and organs. The Company's proprietary
HypoThermosol(R) and CryoStor line of solutions are marketed
directly to companies, labs and academic institutions engaged in
research and commercial applications. BioLife's line of serum free
and protein free preservation solutions are fully defined and
formulated to reduce or prevent preservation-induced, delayed-onset
cell damage and death. BioLife's platform enabling technology
provides academic and clinical researchers significant improvement
in post-thaw cell, tissue, and organ viability and function. For
more information please visit BioLife Solutions website at
www.biolifesolutions.com.
Corning (NYSE:GLW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Corning (NYSE:GLW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024